2.211 The SENSE study: An open-label, single-arm, multicentre, 6-week study evaluating the efficacy and safety of levodopa/carbidopa/entacapone (Stavelo) in Parkinson's disease patients experiencing early re-emergence of symptoms due to wearing-off with conventional medication

2007 ◽  
Vol 13 ◽  
pp. S100
Author(s):  
W.H. Oertel ◽  
K. Eggert ◽  
Ö. Skogar ◽  
K. Amar ◽  
L. Luotonen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Efficacy And Safety ◽  
Open Label ◽  
Conventional Medication ◽  
Wearing Off

scholarly journals LSVT-BIG Improves UPDRS III Scores at 4 Weeks in Parkinson’s Disease Patients with Wearing Off: A Prospective, Open-Label Study

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Tatsuya Ueno ◽  
Megumi Sasaki ◽  
Haruo Nishijima ◽  
Yukihisa Funamizu ◽  
Tomoya Kon ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Open Label ◽  
Advanced Parkinson’S Disease ◽  
Open Label Study ◽  
Motor Disability ◽  
Before And After ◽  
Disease Rating ◽  
Wearing Off

The efficacy of LSVT-BIG for advanced Parkinson’s disease (PD) patients with wearing off remains to be determined. Therefore, we evaluated whether LSVT-BIG improves motor disability in eight PD patients with wearing off. Unified Parkinson’s Disease Rating Scale (UPDRS) scores, daily off time, and mobility assessments were evaluated during the “on” time before and after the LSVT-BIG course. LSVT-BIG significantly improved UPDRS III scores at 4 weeks and UPDRS II scores in the “off” state at 12 weeks, with no changes in the other measures. The findings suggest that LSVT-BIG may be an effective therapy for advanced PD patients with wearing off.

Sign in / Sign up

Export Citation Format

Share Document